

## SECTION III-B

## Hospira's Exhibit List

Hospira's Exhibit List contains the Exhibits that it may present at trial other than for impeachment / cross-examination. Hospira reserves the right to supplement this list in good faith as the case progresses.

Any description of a document on an Exhibit List is provided for convenience only and shall not be used as an admission or otherwise as evidence regarding the listed document or any other listed document.

The listing of an Exhibit does not constitute an admission as to the admissibility of the Exhibit (i.e., a waiver of any applicable objection). Hospira reserves the right to object to the relevance or admissibility of any Exhibit offered by Fresenius Kabi, at the time such Exhibit is offered, in view of the specific context in which such Exhibit is offered, or for any other reason as set forth in the Federal Rules of Evidence or other applicable principles of law.

PTX	Document Date	Description	Beg Bates	End Bates	FK Objections
	9/2015	Precedex label	FK-DEXMED 0000072	FK-DEXMED 0000093	
		ANDA Sec. 2.3Quality Overall Summary in Quality-based Review (QbR) (Dexmedetomidine Hydrochloride in 0.9% Sodium Chloride Injection, 4ug/mL, Terminally Sterilized)	FK-DEXMED 0000340	FK-DEXMED 0000341	R, F
		ANDA 3.2.P.2 Pharmaceutical Development	FK-DEXMED 0000654	FK-DEXMED 0000706	R, F
		ANDA 3.2.P.5.1 Specifications	FK-DEXMED 0001364	FK-DEXMED 0001365	R, F
	6/26/2014	Fresenius Kabi ANDA PR-14-00252 Final Report	FK-DEXMED 0001494	FK-DEXMED 0001568	R, F
		Fresenius Kabi ANDA stability data	FK-DEXMED 0194960	FK-DEXMED 0195036	Y (bates range includes multiple docs)
	7/18/2013	Scenarios for Expedited Development	FK-DEXMED0013437	FK-DEXMED0013442	R, AU, F, H, S
	9/5/2012	Email re DexmedRTU	FK-DEXMED0013634	FK-DEXMED0013634	R, AU, F, H
	10/12/2015	Email re Assistance for bus reviews	FK-DEXMED0085334	FK-DEXMED0085336	R, AU, F, P, S
	1/22/2014	Email chain between c. Nguyen and J. Kao (with attachment)	FK-DEXMED0085627	FK-DEXMED0085630	R, AU, F, P, S
	11/4/2013	Email re Dexmedetomidine RTU NPA	FK-DEXMED0088903	FK-DEXMED0088903	R, AU, F, P, S
	11/4/2013	Attachment to Email re Dexmedetomidine RTU NPA	FK-DEXMED0088916	FK-DEXMED0088917	R, AU, F, P, S
	6/30/2015	Email re Impact of missing leachables data for Dexmed RTU submission	FK-DEXMED0098996	FK-DEXMED0098997	R, AU, F
	7/24/2015	Email re Dexmedetomidine RTU Stability Testing Meeting Discussion	FK-DEXMED0099115	FK-DEXMED0099117	R, AU, F
	9/24/2015	Email re Dexmed RTU Stage Gate - Please Review (with attachment)	FK-DEXMED0099225	FK-DEXMED0099227	R, AU, F
	11/19/2015	Email re dexmed RTU cleaning method	FK-DEXMED0099259	FK-DEXMED0099260	R, AU, F
	4/2/2014	Email chain between P. Torralba and C. Nguyen	FK-DEXMED0116399	FK-DEXMED0116400	P, R
	7/19/2014	Dexmedetomidine RTU (US)	FK-DEXMED0147554	FK-DEXMED0147580	P, R
		Fresenius Kabi Minutes	FK-DEXMED0161128	FK-DEXMED0161134	P, R
	11/2012	FK Project Review Presentation	FK-DEXMED0161493	FK-DEXMED0161501	P, R
		ANDA 1.11 Information Request - Quality	FK-DEXMED0194885	FK-DEXMED0194903	P, R
	10/2016	Fresenius Kabi Proposed Dexmedetomidine Hydrochloride Label	FK-DEXMED0195190	FK-DEXMED0195210	P, R
	1/4/2012	Patent Assignment record	HOSPIRA_00001179	HOSPIRA_00001186	AU, H, R
	8/16/2013	NDA 021038 Prior Approval Supplement re 20 ml premix	HOSPIRA_00002306	HOSPIRA_00003341	H, R
	4/2/2010	Development Report for Precedex Injection 4 mcg-mL initiated by Skora Rev 1.0	HOSPIRA_00872188	HOSPIRA_00872259	H, R, AU, F
	3/13/2013	FDA Approval Letter for NDA 21-038 S-020	HOSPIRA_00876644	HOSPIRA_00876652	H, R, AU, F
	11/15/2014	Email re Precedex Supplements 19, 24, and 26 Approved	HOSPIRA_00878588	HOSPIRA_00878589	H, R, AU, F
		Precedex sNDA Master Production Batch Records	HOSPIRA_00920816	HOSPIRA_00920879	H, R, AU, F
		FDA Letter re NDA 021038 S-019, S-024, and S-026 approval	HOSPIRA_00947428	HOSPIRA_00947464	H, R, AU, F
	4/23/2012	Amended Clinical Study Report	HOSPIRA_01069529	HOSPIRA_01073289	H, R, AU, F

## Hospira's Exhibit List

PTX	Document Date	Description	Beg Bates	End Bates	FK Objections
		Laboratory Notebook Excerpt - 02418	HOSPIRA_01138654	HOSPIRA_01138655	H, R, AU, F
2	8/20/2007	Email re Precedex update	HOSPIRA_01142923	HOSPIRA_01142926	H, R, AU, F
3	4/14/2008	Email re ResourcePlan	HOSPIRA_01143119	HOSPIRA_01143119	H, R, AU, F
4	4/17/2009	Email re Precedex assay specifications	HOSPIRA_01144073	HOSPIRA_01144074	H, R, AU, F
5		Report re Helvoet Omniflex stoppers	HOSPIRA_01144225	HOSPIRA_01144230	H, R, AU, F
6	12/5/2007	Email re Precedex Filter Compatibility	HOSPIRA_01144236	HOSPIRA_01144238	H, R, AU, F
7		Scientific Report re Precedex RTU stability data	HOSPIRA_01144356	HOSPIRA_01144380	H, R, AU, F
8	6/6/2008	Precedex Line Extension Meeting Minutes	HOSPIRA_01144669	HOSPIRA_01144670	H, R, AU, F
9	5/16/2008	Precedex Line Extension Meeting Minutes	HOSPIRA_01145430	HOSPIRA_01145432	H, R, AU, F
0	7/25/2008	Precedex Extension Meeting Minutes	HOSPIRA_01145676	HOSPIRA_01145677	H, R, AU, F
1		Precedex LE PTR Deck	HOSPIRA_01145686	HOSPIRA_01145700	H, R, AU, F
2	4/18/2008	Precedex Line Extension Meeting Minutes	HOSPIRA_01146210	HOSPIRA_01146211	H, R, AU, F
3	10/24/2008	Precedex Line Extension Meeting Minutes	HOSPIRA_01146233	HOSPIRA_01146234	H, R, AU, F
4	9/21/2007	Precedex Line Extension Meeting Minutes	HOSPIRA_01147912	HOSPIRA_01147913	H, R, AU, F
5	1/31/2007	Email re Precedex - Line Extension - Plastics discussion on 1/30/07	HOSPIRA_01150810	HOSPIRA_01150810	H, R, AU, F
6	12/17/1999	FDA Approval Letter re Precedex Concentrate	HOSPIRA_01971227	HOSPIRA_01971231	H, R, AU, F
7	8/1/2016	Stopper Impurity by Ion Trap LC-MS and LC-MS/MS	HOSPIRA_02468291	HOSPIRA_02468308	H, R, AU, F
8		Laboratory Notebook - 01539	HOSPIRA_02497520	HOSPIRA_02497607	H
9		Laboratory Notebook - 02117	HOSPIRA_02498346	HOSPIRA_02498509	H
0		W. Jenkins, PACKAGING DRUGS AND PHARMACEUTICALS (1993)	HOSPIRA_02501967	HOSPIRA_02501973	R
1		Technical Report No. 5 Sterile Pharmaceutical Packaging: Compatibility and Stability	HOSPIRA_02501974	HOSPIRA_02501996	R, F, AU
2		LES, Licensing Executives Society (USA & Canada) Announces 2010 Deals of Distinction Awards ( <a href="https://lesusacanada.site-ym.com/news/266230/Licensing-Executives-Society-USA--Canada-Announces-2010-Deals-of-Distinction-Awards.htm">https://lesusacanada.site-ym.com/news/266230/Licensing-Executives-Society-USA--Canada-Announces-2010-Deals-of-Distinction-Awards.htm</a> )	HOSPIRA_02502341	HOSPIRA_02502346	H, R, AU, F
3		Drugs.com, Benzodiazepenes: Overview and Use ( <a href="https://www.drugs.com/article/benzodiazepines.html">https://www.drugs.com/article/benzodiazepines.html</a> )	HOSPIRA_02502349	HOSPIRA_02502361	H, R
4		FDA.gov, Drug Master Files ( <a href="https://www.fda.gov/Drugs/DevelopmentApprovalProcess/FormsSubmissionRequirements/DrugMasterFilesDMFs/default.htm">https://www.fda.gov/Drugs/DevelopmentApprovalProcess/FormsSubmissionRequirements/DrugMasterFilesDMFs/default.htm</a> )	HOSPIRA_02502362	HOSPIRA_02502376	H, R
5		FDA.gov, The FDA's Drug Review Process: Ensuring Drugs Are Safe and Effective ( <a href="https://www.fda.gov/Drugs/ResourcesForYou/Consumers/ucm143534.htm">https://www.fda.gov/Drugs/ResourcesForYou/Consumers/ucm143534.htm</a> )	HOSPIRA_02502380	HOSPIRA_02502383	H, R
6		FDA.gov, Step 3: Clinical Research ( <a href="https://www.fda.gov/ForPatients/Approvals/Drugs/ucm405622.htm">https://www.fda.gov/ForPatients/Approvals/Drugs/ucm405622.htm</a> )	HOSPIRA_02502384	HOSPIRA_02502388	H, R
7		Royal Society of Chemistry, Periodic Table, <a href="http://www.rsc.org/periodic-table/trends">http://www.rsc.org/periodic-table/trends</a>	HOSPIRA_02502486	HOSPIRA_02502486	R
8	5/7/2013	US Patent No. 8,436,033	HOSPIRA_02502504	HOSPIRA_02502520	R
9	2/3/2017	Decision Denying Institution of Inter Partes Review (US Patent 8,648,106) (Case IPR2016-01580)			R